Pulmonary Arterial Hypertension - Pipeline Review, H1 2017
ReportsWeb.com published “Pulmonary Arterial Hypertension Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
(EMAILWIRE.COM, July 13, 2018 ) Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.
Publisher's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
For more information about this report @ http://www.reportsweb.com/pulmonary-arterial-hypertension-pipeline-review-h1-2017
The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 9, 11, 36, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)
Request a sample copy @ http://www.reportsweb.com/inquiry&RW0001689465/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Actelion Ltd
APT Therapeutics Inc
Arena Pharmaceuticals Inc
Ascendis Pharma A/S
Asklepion Pharmaceuticals LLC
AVEO Pharmaceuticals Inc
Bial - Portela & Ca SA
Camurus AB
Celsion Corp
Celtaxsys Inc
Chiesi Farmaceutici SpA
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Galectin Therapeutics Inc
HitGen LTD
Insmed Inc
INSYS Therapeutics Inc
INVENT Pharmaceuticals Inc
Johnson & Johnson
Kowa Company Ltd
Liquidia Technologies Inc
MannKind Corp
Mast Therapeutics Inc
Mezzion Pharma Co Ltd
miRagen Therapeutics Inc
Morphogen-IX Ltd
Nippon Kayaku Co Ltd
Nippon Shinyaku Co Ltd
Northern Therapeutics Inc
Novartis AG
Peloton Therapeutics Inc
PhaseBio Pharmaceuticals Inc
Pluristem Therapeutics Inc
Polyphor Ltd
Proteo Inc
Pulmokine Inc
Reata Pharmaceuticals Inc
Respira Therapeutics Inc
Reviva Pharmaceuticals Inc
Selten Pharma Inc
Serodus ASA
Silence Therapeutics Plc
SteadyMed Therapeutics Inc
Suda Ltd
Toray Industries Inc
United Therapeutics Corp
Vivus Inc
Inquire for Report @ http://www.reportsweb.com/buy&RW0001689465/buy/2000
Publisher's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
For more information about this report @ http://www.reportsweb.com/pulmonary-arterial-hypertension-pipeline-review-h1-2017
The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 9, 11, 36, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)
Request a sample copy @ http://www.reportsweb.com/inquiry&RW0001689465/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Actelion Ltd
APT Therapeutics Inc
Arena Pharmaceuticals Inc
Ascendis Pharma A/S
Asklepion Pharmaceuticals LLC
AVEO Pharmaceuticals Inc
Bial - Portela & Ca SA
Camurus AB
Celsion Corp
Celtaxsys Inc
Chiesi Farmaceutici SpA
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Galectin Therapeutics Inc
HitGen LTD
Insmed Inc
INSYS Therapeutics Inc
INVENT Pharmaceuticals Inc
Johnson & Johnson
Kowa Company Ltd
Liquidia Technologies Inc
MannKind Corp
Mast Therapeutics Inc
Mezzion Pharma Co Ltd
miRagen Therapeutics Inc
Morphogen-IX Ltd
Nippon Kayaku Co Ltd
Nippon Shinyaku Co Ltd
Northern Therapeutics Inc
Novartis AG
Peloton Therapeutics Inc
PhaseBio Pharmaceuticals Inc
Pluristem Therapeutics Inc
Polyphor Ltd
Proteo Inc
Pulmokine Inc
Reata Pharmaceuticals Inc
Respira Therapeutics Inc
Reviva Pharmaceuticals Inc
Selten Pharma Inc
Serodus ASA
Silence Therapeutics Plc
SteadyMed Therapeutics Inc
Suda Ltd
Toray Industries Inc
United Therapeutics Corp
Vivus Inc
Inquire for Report @ http://www.reportsweb.com/buy&RW0001689465/buy/2000
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results